C56-A Hemolysis, Icterus, and Lipemia/Turbidity Indices as Indicators of Interference in Clinical Laboratory Analysis; Approved Guideline
|
|
- Hortense Hope Shaw
- 6 years ago
- Views:
Transcription
1 C56-A Hemolysis, Icterus, and Lipemia/Turbidity Indices as Indicators of Interference in Clinical Laboratory Analysis; Approved Guideline Presented by: Merle B. Smith, MBA, MS, MT(ASCP) Siemens Healthcare Diagnostics Newark, Delaware, USA Authors Merle B. Smith, MBA, MS, MT(ASCP) Yung W. Chan, MT(ASCP) Alberto Dolci, MD Mark D. Kellogg, PhD Christopher R. McCudden, PhD, DABCC, NRCC Michelle McLean, MS, MT(ASCP) James J. Miller, PhD, DABCC, FACB Jack Zakowski, PhD, FACB 2
2 Acknowledgment Renze Bais, PhD Richard J. Baltaro, MD, PhD, FCAP Cynthia Foss Bowman, MD Jian Dai, PhD, FACB, FCACB Alberto Dolci, MD Raymond E. Karcher, PhD Jeffrey E. Vaks, PhD Jason A. Kellogg, PhD Christopher M. Lehman, MD Karen L. Warren, MS Dror Yahalom, PhD, MBA 3 Intended Use For manufacturers responsible for establishing the automated hemolysis, icterus, and lipemia/turbidity (HIL) detection systems in their clinical laboratory instruments For laboratory directors, managers, supervisors, and medical technologists responsible for establishing or evaluating HIL indices and making judgments about the acceptability of specimens and test results 4
3 Recommendations Establishing HIL indices to assess sample quality Estimating interference effects of hemoglobin, bilirubin, and turbidity Reporting (by manufacturers) hemolysis, icterus, and lipemia/turbidity in the reagent instructions for use (IFU) Establishing error flags for HIL interference Verifying HIL indices in the clinical laboratory Managing potential process outcomes of HIL measurements 5 HIL Indices Hemolysis, icterus, and lipemia/turbidity are common in serum and plasma samples. Each may interfere with certain laboratory tests by optical or chemical mechanisms. These interferents may exert their effects by more than one mechanism. The magnitude and direction of interference may vary with the concentration of the interferent, the number of interferents present, the concentration of the analyte, the specific methodology of the test, and the amount of sample in the final reaction mixture. 6
4 HIL Indices (cont d) HIL indices are (semi)quantitative markers for hemolysis, icterus, and lipemia/turbidity in patient samples. The accuracy and precision of individual H- or I- index estimates should not replace a standard assay for hemoglobin or bilirubin, respectively. 7 Sample Quality Hemolyzed (red) Icteric (yellow) Lipemic (turbid) mg/dl g/l mg/dl µmol/l mg/dl mmol/l * Hemoglobin Total Bilirubin Intralipid * Concentrations based on dilutions of 20% Intralipid (or the equivalent). 8
5 Spectra of Hemoglobin, Bilirubin, and Lipemia/Turbidity In Figure 1, the spectra of bilirubin, hemoglobin, and lipemia/turbidity overlap. However, above 625 nm, the absorbance is due to lipemia/turbidity alone. The spectrum of hemoglobin overlaps most of the spectrum of bilirubin, but absorbance due to hemoglobin without contribution from bilirubin can be measured in the range of 550 to 575 nm. Reprinted with permission from Synermed International, The Infrared Revoluation in Clinical Chemistry Testing. Copyright Syndermed International, Pioneers in Near Infrared Clinical Chemistry. 9 Mechanisms of Hemoglobin Interference Spectral interference: absorbance in the hemoglobin spectral range ( nm; nm; peak = 420) Chemical reactions of heme or its iron with reagent components Release of analytes found in high concentrations in erythrocytes, which will falsely elevate the values of these analytes (eg, K, Mg) Release of enzymes that participate in chemical reactions (eg, AK) 10
6 Mechanisms of Hemoglobin Interference (cont d) Dilutional (water release): release of erythrocyte intracellular fluid, which dilutes analytes Negative interference in haptoglobin assays by hemoglobin binding to haptoglobin Inhibition of reactions: released hemoglobin can directly inhibit chemical reactions, as in polymerase chain reaction based assays on viral and bacterial DNA and RNA 11 Hemolysis Index The H index value closely approximates the hemoglobin concentration in the patient sample. The potassium released by a variable number of erythrocytes is approximately proportional to the H index. However, the amount of potassium per erythrocyte varies due to acid-base and sodiumpotassium balance variation. The correction of potassium results based on the H index is not reliable and is not recommended. When the H index is elevated, a new patient sample free of hemolysis needs to be collected and retested. 12
7 Mechanisms of Bilirubin Interference Spectral interference: absorbance in the bilirubin spectral range ( nm) Chemical reaction with reagent components (eg, H 2 O 2 ) 13 Mechanisms of Lipemia/Turbidity Interference Light scattering due to lipemia/turbidity affects measurements based on light scattering principles, such as nephelometry and turbidimetry. The lipoproteins that are the primary cause of turbidity are the triglyceriderich VLDL and chylomicron fractions. Very low-density lipoprotein (VLDL) exists in three size classes: small (27 35 nm), intermediate (35 60 nm) and large ( nm). Chylomicrons ( nm) vary greatly in size distribution and number among individuals. The degree of scattering depends on the number, size, and refractive index of the suspended particles. Because patient serum or plasma samples are a mixture of various particle sizes, the sample appears lipemic/turbid because the light is scattered at all angles. 14
8 Mechanisms of Lipemia/Turbidity Interference (cont d) Volume exclusion effect due to their large size and hydrophobic nature. Absorption of hydrophobic analytes, reagents, or reaction products into the lipid interior due to their lipophilic nature. Regardless of the cause of turbidity, it results in light scattering. In the absence of a sample blank, light scattering from a sample decreases the spectral operating (linear) range and causes positive interference. Other possible causes of turbidity include erythrocyte debris, platelets, leukocytes, fibrin clots, or contaminating particulate matter. 15 Intralipid * Unlike hemoglobin and bilirubin, there is no simple chemical substance that can be used to mimic the physical/chemical interfering properties of lipemic/turbid samples. Reagent manufacturers use Intralipid (or the equivalent) to simulate lipemia/turbidity. Intralipid is a registered trademark of Fresenius Kabi AG, Bad Homburg, Germany. Intralipid is a synthetic, sterile nonpyrogenic fat emulsion for intravenous administration that can be added to serum or plasma to simulate lipemic samples. The particles in Intralipid (or the equivalent) range in size from 200 to 600 nm (mean 345 nm) and completely miss the range of values for large VLDL and the lower and upper ranges for chylomicrons. Samples with added Intralipid (or the equivalent) do not perfectly mimic lipemic samples. * (or the equivalent) 16
9 Additional Interferences Green biliverdin Brown methemalbumin Orange beta-carotenes Exogenous compounds such as dyes, drugs and contrast media Interfering substances that do not absorb in the visual spectrum (eg, heterophile antibodies) Paraproteins (eg, M-proteins [monoclonal immunoglobulins]). Sample is not visibly lipemic/turbid. Turbidity is created when the sample is mixed with the reagent in the cuvette. 17 Interference Testing for Hemolysis, Icterus, and Lipemia/Turbidity Recommendations for analyte and interferent concentrations for interference testing are based on CLSI document EP07: HIL testing should be performed at two different medical decision levels of the analyte. Clinically significant interference may be missed if testing is performed at one medical decision level. HIL testing should be performed at concentrations representing the various indices to be used. For example: An I index of 1 for bilirubin represents a bilirubin concentration of up to 2 mg/dl (bilirubin testing performed at 2 mg/dl). An index of 2 represents a bilirubin concentration of 2 to 5 mg/dl (bilirubin testing is performed at 5 mg/dl). 18
10 Recommendations The maximum concentration of interferent tested should correspond to the concentration designated at the highest index. For example, hemoglobin is tested up to 1000 mg/dl, thus, the highest H index should include up to 1000 mg/dl of hemoglobin. A manufacturer may perform a: Screening (paired-difference) test followed by a dose-response test if interference is observed during the screening test Dose-response test (skipping the screening test) to assess interference and establish alert indices 19 Materials Used for Determination of Indices Manufacturers should provide information on the type, source, supplier, preparation of the hemolysate, bilirubin (unconjugated, conjugated, or icteric patient samples), and lipemic materials (fat emulsions). CLSI document EP07 may be used in the preparation of hemolysate and unconjugated bilirubin. Lipemic/turbid samples may be prepared by dilutions of the 20% Intralipid (or the equivalent) in serum pools. 20
11 Interferent Test Concentrations The range of hemoglobin concentrations tested should go up to at least 1000 mg/dl, bilirubin to at least 30 mg/dl, and lipemia/turbidity to at least 1000 mg/dl. Index values increase as the interferent concentration increases. 21 Sample Volumes for HIL Testing The volume of sample consumed for index measurements should be provided by the manufacturer. Many samples are available in smaller volumes such as neonatal, geriatric, and critical care. The sample volume required for these precious samples should be minimized to the lowest volume that will yield an accurate measurement. 22
12 Sample Dilution and Diluent Sample dilution and diluent (if applicable) should be specified if and how samples are diluted and what diluent is used (deionized/distilled water, saline [0.9% NaCl], special buffer, etc.). Dilutions and diluents are important considerations to avoid precipitation of paraproteins. 23 Read Wavelengths There is an overlap in the spectra of hemoglobin, bilirubin, and lipemia/turbidity. It is important that appropriate wavelengths and correction methods are used to provide the most accurate concentration estimates. There is currently no defined best method for measuring the serum indices, but manufacturers should describe how they estimate the presence of each interferent and provide information on cross-interferences of hemoglobin, bilirubin, and lipemia/turbidity indices. Detection methods should account for the absorbance spectrum overlap of hemoglobin, bilirubin, and lipemia/turbidity. 24
13 Number of HIL Indices (Bins) The manufacturer should provide the number of indices or "bins" and the concentration ranges associated with each bin. For example, an H index of 1 has a hemoglobin concentration of 10 mg/dl; an H index of 2 has a hemoglobin concentration between 10 and 25 mg/dl. This may be provided graphically, in table form, or as text. The number of indices for each interferent is decided by the manufacturer. It is recommended that a minimum of five "bins" be used (this equates to the standard visual estimation). 25 Number of HIL Indices (Bins) (cont d) There are currently no data to suggest that any particular number of "bins" is of greater utility. Assay imprecision should be considered when determining the number of " bins." Care must be taken in assigning HIL and alert indices to properly flag patient results that are affected by hemolysis, icterus, lipemia/turbidity and avoid false interference flags. 26
14 Read Time Manufacturers should indicate how long it takes to measure each index. The impact of HIL testing on system throughput should be minimized. 27 Calculation Algorithms The presence and degree of hemolysis, icterus, and lipemia/turbidity are detected by measuring the absorbance or reflectance on at least two different wavelengths over the measured spectrum and preferably on the absorbance peaks of the specific substance. Correction factors are required to correct for spectrum overlap for hemoglobin, bilirubin, and lipemia/turbidity. 28
15 Existing Automated HIL Detection Systems on Various Chemistry Analyzers Interferent Material Used HIL System Hemolysis (hemoglobin) Icterus (bilirubin) Lipemia/Turbidity/ Intralipid 1 Erythrocyte Hemolysate Unconjugated 20% Intralipid 2 Erythrocyte Hemolysate Unconjugated 20% Intralipid 3 Erythrocyte Hemolysate Unconjugated 20% Intralipid 4 Erythrocyte Hemolysate and Patient Samples Unconjugated, Conjugated, and Patient Samples 20% Intralipid and Patient Samples 5 Erythrocyte Hemolysate Unconjugated 20% Intralipid 6 Erythrocyte Hemolysate Unconjugated, Patient Samples 7 Erythrocyte Hemolysate Unconjugated, Conjugated 20% Intralipid 20% Intralipid Intralipid (or the equivalent) concentrations were based on dilutions of 20% Intralipid (or the equivalent). 29 Existing Automated HIL Detection Systems on Various Chemistry Analyzers (cont d) Maximum Concentration Tested [mg/dl] HIL System Hemolysis (hemoglobin) Icterus (bilirubin) Lipemia/Turbidity/ Intralipid N/A
16 Existing Automated HIL Detection Systems on Various Chemistry Analyzers (cont d) Sample Volume [ml] Hemolysis Icterus Lipemia/Turbidity HIL System * 35 * 35 * 5 2.0/ / / *The analysis does not consume the sample. 31 Existing Automated HIL Detection Systems on Various Chemistry Analyzers (cont d) Diluent Used/Diluent Volume Used to Determine Hemolysis, Icterus, and Lipemia/Turbidity for Each Sample HIL System Diluent Used Diluent Volume [µl] 1 Water Saline (Reagent 1) Saline (AST/ALT 200 Reagent) 4 Undiluted Undiluted 5 Saline Tris Buffer ph Saline (0.9% NaCl) 150 Abbreviation: AST/ALT, aspartate aminotransferase/alanine aminotransferase. 32
17 Existing Automated HIL Detection Systems on Various Chemistry Analyzers (cont d) Read Wavelength(s) [nm] Hemolysis Icterus (bilirubin) Lipemia/Turbidity/Intralipid HIL System (hemoglobin) 1 405/ / / / / /604; 628/ /524; 572/604; 500/524; 572/604; 572/ / /480; 600/ /570; 600/ / , 340, 470, 600, , 410, 470, 600, , 410, 470, 600, / / / Existing Automated HIL Detection Systems on Various Chemistry Analyzers (cont d) # of HIL Indices/Levels Reported Hemolysis Icterus Lipemia/Turbidity HIL System Concentration reported in Concentration reported in Concentration reported in units units units Concentration reported in units Concentration reported in units 1 60 Concentration reported in units
18 Example of HIL Testing: Hemoglobin Abbreviation: RBC, red blood cell. 35 Alert Index (Threshold Value) An alert index indicates the lowest tested concentration of hemoglobin, bilirubin, and lipemia/turbidity (Intralipid [or the equivalent]) at which the analyte concentration would be falsely increased or decreased. An interference flag is generated if the HIL index of the sample is equal to or exceeds the alert index. At a specific alert index of hemolysis, icterus, and lipemia/turbidity, the interference effect and magnitude of the interference at a specific analyte level is specified in the manufacturer s product labeling. 36
19 Alert Index (Threshold Value) (cont d) When establishing alert indices the manufacturer should consider the following: The magnitude of the bias observed relative to the clinical acceptability criteria. The frequency of false or unnecessary flagging. This may occur if the observed interference is due to the interferent concentration at the upper limit of the concentration range within the HIL index. For example, interference is at 500 mg/dl of hemoglobin; bin of 4 ( mg/dl). No data between mg/dl; using 4 as the alert index, will flag samples containing hemoglobin between 250 and 249 mg/dl causing unnecessary flagging. Customer may consider using 5 ( mg/dl) as the alert index. 37 Gray Zone HIL indices represent estimates of the degree of hemolysis, icterus, and lipemia/turbidity; therefore, the manufacturer may consider defining a gray zone. Gray Zone Indicating Maximum Interferent Concentration With No Known Interference A gray zone may also be established to indicate an HIL index containing a concentration above the highest tested interferent concentration for which no interference data are available. For example: The results of the hemoglobin interference testing for glucose at 100 mg/dl indicated no observed interference up to 1000 mg/dl of hemoglobin. Based on the manufacturer s hemoglobin indices, an H index of 8 indicates a hemoglobin concentration > 1000 mg/dl. An H index of 8 is assigned a gray zone. 38
20 Gray Zone (cont d) The following results are obtained from the dose response (hemoglobin) testing for interference in a glucose assay. The interferograph is as follows: Hemoglobin Glucose mg/dl mg/dl Bias % N/A The allowable bias used for this assay is 10%. Bias outside of ± 10% is considered an interference. The observed percent bias due to hemoglobin for the glucose assay is acceptable. 39 Gray Zone (cont d) The hemoglobin indices are evaluated. Gray Zone H Index Hemoglobin (mg/dl) 1 H < H < H < H < H < H < H H >
21 Gray Zone (cont d) Gray Zone Indicating Potential Interference For each analyte, a gray zone represents the HIL index containing the highest tested interferent concentration that is below or equal to the alert index. This gray zone lies between the highest concentration with acceptable bias and the lowest concentration with known unacceptable bias. For example: The results of the bilirubin interference testing for glucose at 100 mg/dl indicated interference starting at 15 mg/dl of bilirubin. Based on the following bilirubin indices, an I index of 5 is assigned as an alert index while an I index of 4 is assigned as a gray zone. 41 Bilirubin Interference on Glucose Assay Bilirubin Dose Response Testing Interferograph Bilirubin Glucose mg/dl mg/dl Bias % N/A The allowable bias used for this assay is 10%. Bias outside of ± 10% is considered an interference. The bias becomes higher at increasing bilirubin levels. 42
22 Bilirubin Icterus Index Assigned 43 Multiple Interferences More than one HIL interferent may be present simultaneously in a patient sample. The presence of one HIL interferent may adversely affect the measurement of another HIL interferent. Due to the overlapping nature of the absorbance spectra between lipemia/turbidity and the other two interferents, many automated systems have calculation algorithms to correct the raw signals at particular wavelengths to obtain the pure signal and report the index for each individual interferent. 44
23 Wavelength Corrections The H absorbance is read at 405 and 700 nm with correction at 452 nm to prevent high bilirubin samples from generating falsely elevated H index. The I absorbance is read at 452 and 700 nm with correction at 577 nm to minimize falsely high I index due to hemoglobin. The L absorbance is derived from a blanked 700 nm measurement. 45 Verification and Quality Control of HIL Indices in the Clinical Laboratory The manufacturer can verify the sensitivity and specificity of the established HIL indices. The evaluation can consist of assessing the sensitivity of I index to concentrations of hemoglobin and lipids; of H index to concentrations of bilirubin and lipids; and of L index to concentrations of bilirubin and hemoglobin. 46
24 Verifying Specificity of HIL Indices Prepare a sample with low I and L indices, and a medium H index. Aliquot 1 Add a small volume of saline. Aliquot 2 Add bilirubin concentrate equal to the volume of spiking saline. Aliquot 3 Add lipids concentrate equal to the volume of spiking saline. Measure H index of the above aliquots. 47 Verifying Specificity of HIL Indices (cont d) Similarly, effects of H and I indices on lipemia/turbidity, and of H and L indices on icterus, are evaluated using samples with medium levels of lipemia/turbidity and icterus, respectively. Because of the nature of these indices, the results should be considered qualitative or as estimates of the degree of hemolysis, icterus, and lipemia/turbidity. 48
25 Verifying Specificity of HIL Indices (cont d) If the readings of the H index do not change on samples with added bilirubin and lipemia/turbidity, it can be concluded that the H index is not affected by changes in (ie, cross-interferences from) I and L indices for the analytical method being evaluated. If there is a change in the hemolysis index, further investigation should be conducted to make sure there is no interaction between hemoglobin, bilirubin, or lipemia/turbidity, respectively. The number of indices and the range of hemoglobin concentrations within the H index should be considered. 49 Reporting HIL Interference Claims by Manufacturers in Product Labeling Manufacturers provide information on H, I, and L interferences in the reagent package insert or IFU. The information provided includes the concentration of analyte; the concentration of hemoglobin, bilirubin, Intralipid (or the equivalent) tested, respectively; and the bias observed. Interference claims may be listed in one or more of the following sections of the IFU as appropriate: 1) Specimen Collection; 2) Limitations (Interfering Substances); 3) Specificity (HIL Table, Noninterfering Substances). 50
26 Reporting HIL Interference Claims by Manufacturers in Product Labeling (cont d) The interference claim may state the concentration of hemoglobin, bilirubin, Intralipid (or the equivalent), respectively, above which it causes a bias. This represents the lowest tested interferent concentration causing interference. This information is used to establish the alert index for the assay and to alert the user of the potential inaccuracy of the generated analyte result. The interference claim may state the concentration of hemoglobin, bilirubin, and Intralipid (or the equivalent), below which there is no interference. This represents the highest interferent concentration that does not cause interference. 51 Reagent Package Insert/Instructions for Use C56 recommends reporting HIL information in an HIL table format under the Limitations (Interfering Substances) or Specificity sections. Provides information if a particular assay is or is not subject to interference by HIL and includes: Concentration of analyte tested Concentration of hemoglobin, bilirubin, Intralipid (or the equivalent) tested Bias and percent bias (positive or negative) The smallest concentration of hemoglobin, bilirubin, and turbidity that caused an interference and that triggers the alert index to flag an analyte result must be reported in the IFU. 52
27 Instructions for Use: Reporting HIL Interference for Glucose The glucose method was evaluated for interference according to CLSI document EP07. Bias is the difference in the results between the control sample (without the interferent) and the test sample (with the interferent) expressed as a percentage. Bias exceeding 10% is considered interference. Table 1 Substance Tested Substance Concentration Glucose (mg/dl) Bias (%) Hemoglobin (hemolysate) 1000 mg/dl < 10 < 10 Unconjugated bilirubin 60 mg/dl < 10 <10 Lipemia/turbidity (Intralipid [or the equivalent]) 1000 mg/dl <10 <10 53 Instructions for Use: Claims and Alert Indices Assigned Manufacturers that use automated HIL detection systems recommend alert indices based on interference data. HIL IFU claims should align with the HIL indices assigned. Using Table 1, a patient sample with an I index of 5 (15 20 mg/dl of bilirubin) and above, and an L index of 6 ( mg/dl of Intralipid [or the equivalent]) and above, will have the glucose results flagged with bilirubin interference and lipemia/turbidity, respectively. There is no alert index assigned by the manufacturer for hemoglobin because no interference was detected. 54
28 Instructions for Use: HIL Claims The manufacturer may elect to report: Interferent concentration that shows no interference Additional concentrations of the interferent to demonstrate the actual concentration at which interference is first detected, and the highest interferent concentration tested In this example, interference is observed starting at 250 mg/dl of hemoglobin. The highest hemoglobin concentration tested is 500 mg/dl. Substance Tested Substance Concentration (mg/dl) Glucose (mg/dl) Bias (%) Hemolysis < 10 (hemoglobin) 250 < Instructions for Use: Reporting Example 1 When there is no interference: The highest concentration of hemoglobin, bilirubin, and Intralipid (or the equivalent) tested should be reported in the IFU. For example: hemoglobin at 1000 mg/dl; bilirubin at 60 mg/dl; Intralipid (or the equivalent) at 1000 mg/dl. Substance Tested Substance Concentration Glucose (mg/dl) Bias (%) Hemoglobin (hemolysate) 1000 mg/dl < 10 < 10 Unconjugated bilirubin 60 mg/dl < 10 <10 Lipemia/turbidity (Intralipid [or the equivalent]) 1000 mg/dl <10 <10 The alert indices to be assigned for this assay will be: H = 8; I = 8; L = 8 (corresponding to H > 1000 mg/dl, I > 60 mg/dl, and L > 1000 mg/dl). 56
29 Instructions for Use: Reporting Example 2 57 Instructions for Use: Reporting Example 2 (cont d) Manufacturers that use automated HIL detection systems recommend alert indices based on interference data. Icterus and lipemia indices of 5 and 6, respectively, will be assigned as alert indices for this assay because they are the bins that contain 15 mg/dl of bilirubin and 600 mg/dl of lipemia/turbidity (Intralipid [or the equivalent]). 58
30 Instructions for Use: Reporting Example 3 59 Instructions for Use: Reporting Example 4 60
31 Potential Process Outcomes of HIL Measurements/Estimates 61 Laboratory Guidelines It is recommended that the laboratory establish its own guidelines for addressing patient samples that have HIL error flags, such as when reporting interference error flags without results, rejecting the patient results, redrawing the specimens with considerations given to neonatal and geriatric populations, and notifying the health care provider (physician), which includes documenting the dialogue conducted with the physician. Laboratories must follow the regional, national, and local regulatory agencies for current applicable requirements. 62
32 HIL Reporting of HIL Indices/Flags Laboratories employ middleware or laboratory information systems for autoverification. Rules or algorithms can be used to alert laboratory personnel of error messages, including HIL flags. If the HIL index is below the alert index designated for the assay, there is no HIL interference and the assay result is reported. If the HIL index is equal to or greater than the alert index, the result is flagged with either the appropriate H, I, L comment indicating potential interference. The laboratory is responsible for rejecting, reporting, and handling of samples and test results that have been flagged with interference errors. 63 Example of Reporting HIL Indices 64
33 Verification and Quality Control of HIL Indices in the Clinical Laboratory Though HIL indices may not be subject to the requirements specified by regulatory and/or accrediting agencies for analysis of clinical specimens, laboratories should consider verification and Quality Control (QC) of expected performance of these parameters before (verification) and after (QC) implementation into laboratory practice. Because HIL parameters are produced using spectrophotometric measurements, they are subject to drift and failure like any standard spectrophotometric assay. Failure to maintain consistent measurements over time may lead to changes in the effective criteria for acceptance or rejection of specimens received by the laboratory. In addition, variability between analyzers may result in inconsistent acceptance/rejection criteria. To date, no HIL standards (calibrators) are available for use. 65 Verification and Quality Control of HIL Indices in the Clinical Laboratory (cont d) Visual examination of patient specimens for comparison with HIL indices is not recommended, because it has been shown to be inaccurate and variable due to its qualitative and subjective nature. For verifying the HIL indices, laboratories may consider the following options: The laboratory can challenge the HIL flagging system using hemolysates, and samples with added bilirubin and Intralipid (or the equivalent), respectively (see CLSI document EP07), that span the range of the H and I values that would generate a flag when exceeded. The laboratory may be able to use samples that are provided by a health care organization and are designated for verifying HIL interference effects using doseresponse methodology. The laboratory can measure the hemoglobin (eg, cyanmethemoglobin methodology) and bilirubin (total and direct) concentrations of patient specimens that have been evaluated by the instrument HIL system. 66
34 Verification and Quality Control of HIL Indices and Alert Indices in the Clinical Laboratory Each laboratory should consult with its manufacturers to identify the appropriate control materials for monitoring the performance of HIL parameters over time. For monitoring the H parameter, one option is to prepare a hemolysate for use as QC material for a period of time as validated by the laboratory. For monitoring the I parameter, one option is a total bilirubin control that is used daily in the laboratory for the bilirubin assay. For monitoring the L parameter, one option is to make up lipemia/turbidity controls by spiking Intralipid (or the equivalent) into serum or plasma at the desired concentration, aliquotting, and freezing for storage. Because HIL determinations are spectrophotometric measurements, monitoring and basic troubleshooting should include general spectrophotometric instruments/device investigations. 67 Verification and Quality Control of HIL Indices in the Clinical Laboratory The laboratory may be able to use samples that are provided by a health care organization and are designated for verifying HIL interference effects using dose-response methodology. These samples contain varying concentrations of interferents (hemoglobin, bilirubin) that can be analytically measured using the clinical instrumentation in the laboratory. The measured interferents (hemoglobin, bilirubin) may then be checked against the range of concentrations assigned for H and I indices provided by the manufacturers. These samples can also be measured for various analytes of interest. 68
35 Verification and Quality Control of HIL Indices in the Clinical Laboratory (cont d) The accuracy of interference flagging based on the assigned alert indices and interference claims made by the manufacturer can be evaluated. Each laboratory should consult with its manufacturers to identify the appropriate control materials for monitoring the performance of HIL parameters over time. 69 Conclusions C56-A Hemolysis, Icterus, and Lipemia/Turbidity Indices as Indicators of Interference in Clinical Laboratory Analysis; Approved Guideline focuses on the intended usefulness and challenging issues of HIL indices as estimates of interference that may impact the validity and clinical utility of reportable patient results. This document enhances the continuous education of health care personnel by explaining the mechanisms of HIL interference, which in some cases include the noncorrelation of visual and (semi)quantitative HIL indices, the strengths and limitations of HIL measurements, and the verification of HIL indices in the clinical laboratory. 70
36 Questions? 71 Thank You Be sure to download the PACE CE Evaluation PACE credits are available for those participating in the live webinar only. In order to receive your PACE credits please download this form and or fax the form back to us You may now disconnect
Patient: 55 y female (ambulatory)
Disclosures Speaking Honoraria Radiometer (Canada) Nova Biomedical, Draeger Roche Diagnostics (Canada) Research Support (Reagents, Instrumentation, Travel) Nova Biomedical Abbott Laboratories (Canada)
More informationPresented by Marcelo Cardona, MT(ASCP) Johns Hopkins University
Presented by Marcelo Cardona, MT(ASCP) Johns Hopkins University Alert or critical values represent those assay results that require prompt, rapid clinical attention to avert significant study-participant
More informationGLUH PRINCIPLE REF B ANNUAL REVIEW Reviewed by. Date. Date INTENDED USE
SYNCHRON System(s) Chemistry Information Sheet Copyright 2014 Beckman Coulter, Inc. GLUH Glucose REF B24985 For In Vitro Diagnostic Use Rx Only ANNUAL REVIEW Reviewed by Date Reviewed by Date PRINCIPLE
More informationThe Adiponectin Turbidimetric Immunoassay Reagent Kit
The Adiponectin Turbidimetric Immunoassay Reagent Kit Catalogue number: 51010 For the quantitative determination of Adiponectin in human serum and plasma This package insert must be read in its entirety
More informationThe Virtues and Pitfalls of Implementing a New Test
The Virtues and Pitfalls of Implementing a New Test James H. Nichols, Ph.D., DABCC, FACB Professor of Clinical Pathology, Microbiology and Immunology Associate Medical Director for Clinical Operations
More informationReferences Required document for Laboratory Accreditation by the College of American Pathologists.
Subject Hemoglobin A1c Cobas c501 Index Number Lab-4004 Section Laboratory Subsection Chemistry Category Departmental Contact Benjamin Michel Last Revised 9/12/2016 References Required document for Laboratory
More informationIDEXX Catalyst One Chemistry Analyzer for In-house Measurement of Total Thyroxine (TT 4 ) Concentration in Serum from Dogs and Cats
IDEXX Catalyst One Chemistry Analyzer for In-house Measurement of Total Thyroxine (TT 4 ) Concentration in Serum from Dogs and Cats Authors: Kate Cote, Ph.D., Graham Bilbrough, MA, VetMB, CertVA, MRCVS,
More informationHuman Hemoglobin Colorimetric Detection Kit
Human Hemoglobin Colorimetric Detection Kit CATALOG NO: IRAAKT2522 LOT NO: SAMPLE INTENDED USE The Hemoglobin detection kit is designed to quantitatively measure all forms of hemoglobin present in blood
More informationUse of PSI on CS instruments
Johan Claes, Version 01, 1 st September 2016 User day hemostasis 2016 Use of PSI on CS instruments Restricted Siemens Healthcare GmbH, 2016 Hemostasis Lab Challenges Preanalytical problems in Haemostasis
More informationApplicable To Employees of the Gundersen Boscobel Area Hospital Laboratory and Gundersen Palmer Lutheran Hospital and Clinics laboratories.
Subject Calcium C311 Index Number Lab-8810 Section Laboratory Subsection Regional/Affiliates Category Departmental Contact Judy Dayton Last Revised 4/11/2017 References Required document for Laboratory
More informationGentian Canine CRP Immunoassay Application Note for Abbott Architect * c4000
v2-jan214 Gentian Canine CRP Immunoassay Application Note for Abbott Architect * c4 Intended Use The canine CRP immunoassay on Abbott's Architect c4 is an in vitro diagnostic test for quantitative determination
More informationQMS TACROLIMUS APPLICATION BECKMAN COULTER AU480 /AU680 /AU5800
QMS TACROLIMUS APPLICATION BECKMAN COULTER AU480 /AU680 /AU5800 Beckman Coulter Reagent REF A53727 The QMS Tacrolimus Immunoassay is intended for the quantitative determination of tacrolimus in human whole
More informationCoping with Analytical Interferences
Coping with Analytical Interferences (Handling Icteric, Hemolytic and Lipaemic Samples) Graham Jones Department of Chemical Pathology St Vincent s Hospital, Sydney Surabaya Indonesia 2016 Acknowledgements
More information1 Introduction Imprecision Within-run imprecision, results Day-to-day imprecision, results... 2
Design Verification liquicolor 1 Introduction... 2 2 Imprecision... 2 2.1 Within-run imprecision, results... 2 2.2 Day-to-day imprecision, results... 2 3 Linearity and Detection Limit... 2 3.1 Linearity...
More informationClinical Chemistry Specific Proteins Presentation
Clinical Chemistry Specific Proteins Presentation November 2004 AEROSET and c8000 are registered trademarks of Abbott Laboratories. All other trademarks, brands, trade names and product names are the property
More informationOriginal Article Interfering effect of bilirubin on the determination of alkaline phosphatase
Int J Clin Exp Med 2014;7(11):4244-4248 www.ijcem.com /ISSN:1940-5901/IJCEM0002083 Original Article Interfering effect of bilirubin on the determination of alkaline phosphatase Zhong Wang, Hongyan Guo,
More informationFor In Vitro Diagnostic Use. Rx Only. Reviewed by Date Reviewed by Date
SYNCHRON System(s) Chemistry Information Sheet 2015 Beckman Coulter, Inc. All rights reserved. HDLD HDL Cholesterol 650207 For In Vitro Diagnostic Use ANNUAL REVIEW Rx Only Reviewed by Date Reviewed by
More informationApplicable To Employees of Gundersen Boscobel Area Hospital Laboratory and Gundersen Palmer Lutheran Hospital and Clinics Laboratory.
Subject Creatinine COBAS C311 Index Number Lab-8814 Section Laboratory Subsection Regional/Affiliates Location Category Departmental Contact Tilleraas, Betty Last Revised 1/17/2018 References Required
More informationApplicable To Employees of Gundersen Boscobel Area Hospital laboratory and Gundersen Palmer Lutheran Hospital and Clinic Laboratories.
Subject Sodium Potassium Chloride ISE - C311 Index Number Lab-8828 Section Laboratory Subsection Regional/Affiliates Category Departmental Contact Betty Tilleraas Last Revised 4/12/2017 References Required
More information25-Hydroxy Vitamin D TOTAL (25HD) on Liaison XL
25-Hydroxy Vitamin D TOTAL (25HD) on Liaison XL I. PRINCIPLE The role of vitamin D in bone and mineral metabolism was recognized from its first identification as a factor that could cure rickets. However,
More information02006B 1 vial 02006B 1 vial Store at -20 C. Lyophilized recombinant IL-2
For detection and measurement of human interleukin 2 Catalog #02006 Catalog #02007 2 Plates 10 Plates Product Description The Human Interleukin 2 (IL-2) ELISA Kit is designed for the quantitative detection
More informationUSING THE ACCESS AMH ASSAY IN YOUR LABORATORY
INFORMATION BULLETIN USING THE ACCESS AMH ASSAY IN YOUR LABORATORY ///////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////
More informationDelta Check Calculation Guide
Delta Check Calculation Guide National Technology 2017, All Rights Reserved By Senior Scientific Researcher, Asmaa Taher Table of Contents Definition... 2 Purpose... 2 Delta Check Research Studies... 2
More informationMETHOD VALIDATION CASE
METHOD VALIDATION CASE METHOD VALIDATION PROTOCOL CLIA Regulation 493.1253 (2) 1.Accuracy (closeness to true/comparative method) 2.Precision (reproducibility) 3.Reference Interval 4.Reportable range (linearity,
More information510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY AND INSTRUMENT COMBINATION TEMPLATE
A. 510(k) Number: k100322 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY AND INSTRUMENT COMBINATION TEMPLATE B. Purpose for Submission: Clearance of a new device C. Measurand: Whole
More informationWhite Paper, Evaluation of WaveSense JAZZ Blood Glucose Monitoring System Analytical Performance to EN ISO 15197:2015 Standard
White Paper, Evaluation of WaveSense JAZZ Blood Glucose Monitoring System Analytical Performance to EN ISO 15197:2015 Standard 7500-10032 Rev F Table of Contents Executive Summary 3 Changes introduced
More informationFor In Vitro Diagnostic Use
SYNCHRON System(s) Chemistry Information Sheet Lactate REF A95550 For In Vitro Diagnostic Use ANNUAL REVIEW Refer to Review and Revision Coversheet at the front of each method. PRINCIPLE INTENDED USE reagent,
More informationMETHOD VALIDATION: WHY, HOW AND WHEN?
METHOD VALIDATION: WHY, HOW AND WHEN? Linear-Data Plotter a,b s y/x,r Regression Statistics mean SD,CV Distribution Statistics Comparison Plot Histogram Plot SD Calculator Bias SD Diff t Paired t-test
More informationCustomer Bulletin. Questions/Comments? Please call Customer Service at (Direct) or (Toll-free inside USA).
Customer Bulletin Assignment of Ranges for PTS Panels Multi-Chemistry Controls (Cat. No./REF 721) and PTS Panels Controls (Cat. No./REF 722) Background: PTS Panels Multi-Chemistry Controls and Controls
More informationSAMPLE. Clinical and Laboratory Standards Institute Advancing Quality in Health Care Testing
Vol. 32 No. 12 Replaces EP27-P Vol. 29 No. 16 How to Construct and Interpret an Error Grid for Quantitative Diagnostic Assays; Approved Guideline This guideline describes what an error grid is, why it
More informationDRI METHAQUALONE APPLICATION BECKMAN COULTER AU5800
DRI METHAQUALONE APPLICATION BECKMAN COULTER AU5800 Catalog No. 0514, 0515 Homogeneous Enzyme Immunoassay for the Qualitative and Semiquantitative Determination of Methaqualone Levels in Urine For In Vitro
More informationUse of PSI on CS instruments
Johan Claes, Version 01, 1 st September 2016 User day hemostasis 2016 Use of PSI on CS instruments Restricted Siemens Healthcare GmbH, 2016 Hemostasis Lab Challenges Preanalytical problems in Haemostasis
More informationGentian Canine CRP Immunoassay Application Note for scil VitroVet*
v02-jan2014 Gentian Canine CRP Immunoassay Application Note for scil VitroVet* Intended Use The canine CRP immunoassay on scil VitroVet is an in vitro diagnostic test for quantitative determination of
More informationTechnical Bulletin No. 162
CPAL Central Pennsylvania Alliance Laboratory Technical Bulletin No. 162 cobas 6800 HCV Viral Load Assay - New Platform - June 1, 2017 Contact: Heather Habig, MLS (ASCP) CM, MB CM, 717-851-1422 Operations
More informationMethod Comparison Report Semi-Annual 1/5/2018
Method Comparison Report Semi-Annual 1/5/2018 Prepared for Carl Commissioner Regularatory Commission 123 Commission Drive Anytown, XX, 12345 Prepared by Dr. Mark Mainstay Clinical Laboratory Kennett Community
More information510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE A. 510(k) Number: k103542 B. Purpose for Submission: Alternative blood glucose test strips for use with LifeScan OneTouch
More informationBÜHLMANN fcal turbo. Calprotectin turbidimetric assay for professional use. Reagent Kit B-KCAL-RSET. Revision date:
BÜHLMANN fcal turbo Calprotectin turbidimetric assay for professional use Reagent Kit B-KCAL-RSET Revision date: 2017-02-24 BÜHLMANN LABORATORIES AG Baselstrasse 55 4124 Schönenbuch, Switzerland Tel.:
More informationProcine sphingomyelin ELISA Kit
Procine sphingomyelin ELISA Kit For the quantitative in vitro determination of Procine sphingomyelin concentrations in serum - plasma - celiac fluid - tissue homogenate - body fluid FOR LABORATORY RESEARCH
More informationSeeing is not Believing (13-Nov-2004)
In: 55th Annual Meeting of the American College of Veterinary Pathologists (ACVP) & 39th Annual Meeting of the American Society of Clinical Pathology (ASVCP), ACVP and ASVCP (Eds.) Publisher: American
More informationG. Snodgrass, K. Ackles, A. Blanco and A. Versaggi Ortho Clinical Diagnostics, Rochester, NY 14626
Performance of the EKF Diagnostics, Stanbio β-hydroxybutyrate LiquiColor Assay on the VITROS 4600 Chemistry System and the VITROS 5600 Integrated System. G. Snodgrass, K. Ackles, A. Blanco and A. Versaggi
More informationReferences Required document for Laboratory Accreditation by the College of American Pathologists.
Subject NT-proBNP Cobas e601 Index Number Lab-4011 Section Laboratory Subsection Chemistry Category Departmental Contact Benjamin Michel Last Revised 10/19/2016 References Required document for Laboratory
More informationCEDIA OPIATE APPLICATION BECKMAN COULTER AU5800
CEDIA OPIATE APPLICATION BECKMAN COULTER AU5800 Catalog No. 100089, 100098, 1661248 Intended for the qualitative and semiquantitative determination of opiates in human urine For In Vitro Diagnostic and
More informationThyroid Stimulating Hormone (S-TSH) Thyroid Stimulating
ab108659 Thyroid Stimulating Hormone (S-TSH) Human ELISA Kit Instructions for Use For the quantitative measurement of Human Thyroid Stimulating Hormone (S-TSH) concentrations in serum. This product is
More informationTechnical Bulletin No. 161
CPAL Central Pennsylvania Alliance Laboratory Technical Bulletin No. 161 cobas 6800 HIV-1 Viral Load Assay - New Platform - June 1, 2017 Contact: Heather Habig, MLS (ASCP) CM, MB CM, 717-851-1422 Operations
More informationThis package insert contains information to run the Prealbumin assay on the ARCHITECT c Systems and the AEROSET System.
PREALBUMIN 1E02-21 304381/R1 PREALBUMIN This package insert contains information to run the Prealbumin assay on the ARCHITECT c Systems and the AEROSET System. NOTE: This package insert must be read carefully
More informationAspartate Aminotransferase Test Code: AST
Aspartate Aminotransferase Test Code: AST Intended Use For in vitro diagnostic use only CARESIDE Aspartate Aminotransferase (AST) cartridges are used with the CARESIDE Analyzer to quantitatively measure
More informationStandard Operating Procedure
Subject Free Thyroxine (FT4-II) cobas e411 Index Number Lab-1594 Section Regional/Affiliate Subsection Laboratory Category Departmental Contact Goplin, Darcy Last Revised 2/2/2017 References Required document
More informationBasic knowledge of POCT instuments. The Tide Resort Bangsan Beach 18 June 2009
Basic knowledge of POCT instuments The Tide Resort Bangsan Beach 18 June 2009 1 POCT instruments concepts Point of care testing Diagnostic medical devices used at or near the site of patient care Bed site,
More informationCLINITEK Novus Automated Urine Chemistry Analyzer
CLINITEK, Atlas, Novus, Status+, and all associated marks are trademarks of Siemens Healthcare Diagnostics Inc. or its affiliates. All other trademarks are properties of their respective owners. Product
More informationFor in vitro diagnostic use only. For Rx use only. Reviewed by Date Reviewed by Date
AU US Instructions For Use 2018 Beckman Coulter, Inc. All rights reserved. TRIG TRIGLYCERIDE OSR60118 4 x 20 ml R1, 4 x 5 ml R2 OSR61118 4 x 50 ml R1, 4 x 12.5 ml R2 OSR66118 4 x 173 ml R1, 4 x 48 ml R2
More informationMETHOD VALIDATION CASE
METHOD VALIDATION CASE METHOD VALIDATION PROTOCOL CLIA Regulation 493.1253 (2) 1.Accuracy (closeness to true/comparative method) 2.Precision (reproducibility) 3.Reference Interval 4.Reportable range (linearity,
More informationDetermination of hemoglobin is one of the most commonly
ORIGINAL ARTICLE Multiple-Site Analytic Evaluation of a New Portable Analyzer, HemoCue Hb 201+, for Point-of-Care Testing Sten-Erik Bäck, PhD,* Carl G. M. Magnusson, PhD, Lena K. Norlund, MD, PhD, Henning
More informationThis package insert contains information to run the Cholesterol assay on the ARCHITECT c Systems.
en CHOLESTEROL 7D62 304796/R02 CHOLESTEROL This package insert contains information to run the Cholesterol assay on the ARCHITECT c Systems. Read Highlighted Changes Revised October 2012 Package insert
More informationHexagon PSA. Design Verification. Contents
Design Verification Hexagon PSA Contents 1. Function...2 2. Sensitivity, Dynamic Range and Traceability...2 Description of Control Materials...2 Analytical Sensitivity...2 3. Clinical Evaluation...3 Evaluation
More informationIDEXX Catalyst SDMA Test for in-house measurement of SDMA concentration in serum from dogs and cats
IDEXX Catalyst SDMA Test for in-house measurement of SDMA in serum from dogs and cats By Graham Bilbrough, Barbara Evert, Karen Hathaway, Gina Panagakos, Jane Robertson, and Maha Yerramilli Introduction
More informationHemoCue Hb METHOD AND SAMPLE COLLECTION
HemoCue Hb 201 + METHOD AND SAMPLE COLLECTION 1. PURPOSE AND SCOPE The purpose of this document is to describe the procedure for performing a Haemoglobin (Hb) test using the HemoCue Hb 201 + analyser.
More informationFinTest IgG4 Screen 20 ELISA KIT
FinTest IgG4 Screen 20 ELISA KIT Cat. No.:DEIA6196 Pkg.Size:96T Intended use Enzyme immunoassay (microtiter strips) for the detection and the quantitative determination of IgG4 antibodies against 20 Food
More informationThe ABL800 FLEX Setting the standard
The ABL800 FLEX Setting the standard SIMPLY DEDICATED Setting the standard for fast and reliable measurements A look behind Radiometer s superior sensor technology Since the introduction, Radiometer s
More informationThe NGAL Turbidimetric Immunoassay Reagent Kit
Antibody and Immunoassay Services Li Ka Shing Faculty of Medicine, University of Hong Kong The NGAL Turbidimetric Immunoassay Reagent Kit Catalogue number: 51300 For the quantitative determination of NGAL
More informationFarouk AL Quadan lecture 3 Implentation of
How to implement a program? Establish written policies and procedures Assign responsibility for monitoring and reviewing Train staff Obtain control materials Collect data Set target values (mean, SD) Establish
More informationFor in vitro Veterinary Diagnostics only. Kylt Rotavirus A. Real-Time RT-PCR Detection.
For in vitro Veterinary Diagnostics only. Kylt Rotavirus A Real-Time RT-PCR Detection www.kylt.eu DIRECTION FOR USE Kylt Rotavirus A Real-Time RT-PCR Detection A. General Kylt Rotavirus A products are
More informationThis package insert contains information to run the Cholesterol assay on the ARCHITECT c Systems and the AEROSET System.
CHOLESTEROL 7D62-21 304342/R1 CHOLESTEROL This package insert contains information to run the Cholesterol assay on the ARCHITECT c Systems and the AEROSET System. NOTE: This package insert must be read
More informationThyroxine (T4) Human ELISA Kit
ab108662 Thyroxine (T4) Human ELISA Kit Instructions for Use For the quantitative measurement of Human Thyroxine (T4) concentrations in serum. This product is for research use only and is not intended
More informationDiagnostic reagent for quantitative in vitro determination of Urea / Blood Urea Nitrogen in serum, plasma and urine by colorimetry.
2013/07/30 A93A01315AUS A11A01641 60 ml 15 ml Pentra C400 Diagnostic reagent for quantitative in vitro determination of Urea / Blood Urea Nitrogen in serum, plasma and urine by colorimetry. QUAL-QA-TEMP-0846
More informationHbA1c (Human) ELISA Kit
HbA1c (Human) ELISA Kit Cat. No.:DEIA3509 Pkg.Size:96T Intended use GHbA1c (Human) ELISA Kit is a sandwich enzyme immunoassay for the quantitative measurement of human GHbA1c. General Description vhemoglobin,
More informationliquicolor Design Verification
Design Verification liquicolor 1 Introduction... 2 2 Imprecision... 2 2.1 Imprecision for... 2 2.2 Imprecision for... 2 3 Linearity and Detection Limit... 2 3.1 Linearity... 2 3.2 Detection Limit... 4
More informationAbbott Cell-Dyn Reticulocyte Method Comparison and Reticulocyte Normal Reference Range Evaluation
Laboratory Hematology 8:85-90 2002 Carden Jennings Publishing Co.. Ltd. Abbott Cell-Dyn Reticulocyte Method Comparison and Reticulocyte Normal Reference Range Evaluation T. SCHISANO, L. VAN HOVE Abbott
More informationEvaluation Report: Eurolyser CRP test (ST0100 and ST0102) on. CUBE analyser (CA0100)
Evaluation Report: Eurolyser CRP test (ST0100 and ST0102) on CUBE analyser (CA0100) Location Location: Eurolyser Diagnostica GmbH Operators: Simone Wieser; Franz Helminger; Michael Gruber Date: July-November
More informationAPOLIPOPROTEIN A1. This package insert contains information to run the Apolipoprotein A1 assay on the ARCHITECT c Systems and the AEROSET System.
APOLIPOPROTEIN A1 9D92-20 304511/R5 APOLIPOPROTEIN A1 This package insert contains information to run the Apolipoprotein A1 assay on the ARCHITECT c Systems and the AEROSET System. NOTE: Changes Highlighted
More informationChorionic Gonadotropin Human ELISA Kit
ab108637 Chorionic Gonadotropin Human ELISA Kit Instructions for Use For the qualitative measurement of Human Chorionic Gonadotropin concentrations in serum and urine. This product is for research use
More informationCAP Laboratory Improvement Programs. Utility of Repeat Testing of Critical Values. A Q-Probes Analysis of 86 Clinical Laboratories
CAP Laboratory Improvement Programs Utility of Repeat Testing of Critical Values A Q-Probes Analysis of 86 Clinical Laboratories Christopher M. Lehman, MD; Peter J. Howanitz, MD; Rhona Souers, MS; Donald
More informationHuman cholesterol, CH ELISA Kit
Human cholesterol, CH ELISA Kit Catalog No: E1701h 96 Tests Operating instruction www.eiaab.com FOR RESEARCH USE ONLY; NOT FOR THERAPEUTIC OR DIAGNOSTIC APPLICATIONS! PLEASE READ THROUGH ENTIRE PROCEDURE
More informationHigh-density Lipoprotein Cholesterol (HDL-C) Assay Kit
(FOR RESEARCH USE ONLY. DO NOT USE IT IN CLINICAL DIAGNOSIS!) High-density Lipoprotein Cholesterol (HDL-C) Assay Kit (Double reagents) Catalog No: E-BC-K221 Method: Colorimetric method Specification: 96T
More informationBovine Insulin ELISA
Bovine Insulin ELISA For quantitative determination of insulin in bovine serum and plasma. For Research Use Only. Not For Use In Diagnostic Procedures. Catalog Number: 80-INSBO-E01 Size: 96 wells Version:
More informationACTG Laboratory Technologist Committee Revised Version 2.0 ACTG Lab Man Coulter HIV-1 p24 ELISA May 21, 2004
Coulter HIV p24 1. PRINCIPLE The Human Immunodeficiency Virus Type 1 (HIV-1) is recognized as the etiologic agent of acquired immunodeficiency syndrome (AIDS). The virus is transmitted by sexual contact,
More informationLaboratory management of haemolysed samples results of an RCPAQAP survey. Penny Petinos
Laboratory management of haemolysed samples results of an RCPAQAP survey Penny Petinos Agenda Background to KIMMS survey on haemolysis Results of the 2010 and 2014 surveys Outcomes/decisions 2 Background
More informationInsulin Aspart ELISA Kit
Insulin Aspart ELISA Kit Catalogue DEIABL215 For the qualitative determination of antibodies to insulin aspart in human serum and plasma FOR RESEARCH USE ONLY Creative Diagnostics. All rights reserved
More informationCanine Thyroid Stimulating Hormone, TSH ELISA Kit
Canine Thyroid Stimulating Hormone, TSH ELISA Kit Catalog No: E0463c 96 Tests Operating instruction www.eiaab.com FOR RESEARCH USE ONLY; NOT FOR THERAPEUTIC OR DIAGNOSTIC APPLICATIONS! PLEASE READ THROUGH
More informationExendin-4 (Exenatide) ELISA Kit
Exendin-4 (Exenatide) ELISA Kit Catalog: DEIABL227 For the quantitative determination of Exendin-4 in serum or plasma using competitive ELISA method For Research Use Only. Protocol Provided for Informational
More informationHbA1c3 PRINCIPLE REF B ANNUAL REVIEW Reviewed by. Date. Date INTENDED USE
SYNCHRON System(s) Chemistry Information Sheet Copyright 2014 Beckman Coulter, Inc. HbA1c3 Hemoglobin A1c3 REF B36415 For In Vitro Diagnostic Use Rx Only ANNUAL REVIEW Reviewed by Date Reviewed by Date
More informationEvaluation of VACUETTE Urine CCM Tubes for Urine Strip Testing
Evaluation of VACUETTE Urine CCM Tubes for Urine Strip Testing Background The VACUETTE Urine is for the collection, transport and storage of urine samples for urine culture and urinalysis in the laboratory.
More informationAldosterone on Liaison XL In use date: June 6, 2017
Aldosterone on Liaison XL In use date: June 6, 2017 I. PRINCIPLE Aldosterone is a steroid hormone of molecular weight 360.4 daltons, the major mineralcorticoid secreted by the adrenal cortex. The role
More informationParvovirus B19 IgM Human ELISA Kit
ab108760 Parvovirus B19 IgM Human ELISA Kit Instructions for Use For the qualitative determination of IgM class antibodies against Parvovirus B19 in Human serum or plasma (citrate). This product is for
More informationFish follicle-stimulating hormone, FSH ELISA Kit
Fish follicle-stimulating hormone, FSH ELISA Kit Catalog No: E0830f 96 Tests Operating instruction www.eiaab.com FOR RESEARCH USE ONLY; NOT FOR THERAPEUTIC OR DIAGNOSTIC APPLICATIONS! PLEASE READ THROUGH
More informationChallenges in Performing a Scientifically Meaningful Lipemic Plasma Test in Bioanalytical Method Validation
Challenges in Performing a Scientifically Meaningful Lipemic Plasma Test in Bioanalytical Method Validation Laurence Mayrand-Provencher, Milton Furtado, Jean- Nicholas Mess, Josée Michon, Annik Bergeron,
More information1. Reagent Store at 2-8 ºC.
LDL Insert Ref.:146 Intended use. System for direct quantitative determination of low density lipoprotein (LDL) in serum or plasma samples. Professional use. [For in vitro diagnostic use.] Test principle.
More informationHuman HBcAb IgM ELISA kit
Human HBcAb IgM ELISA kit Catalog number: NR-R10163 (96 wells) The kit is designed to qualitatively detect HBcAb IgM in human serum or plasma. FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC PURPOSES
More informationIVD Revised 22 July, 2008
INTENDED USE The DRG One Step HCG Pregnancy Test is an in vitro diagnostic test for the qualitative detection of human chorionic gonadotropin (hcg) in urine. The test is a two-site immunoassay employing
More informationInsulin (Porcine/Canine) ELISA
Insulin (Porcine/Canine) ELISA For the quantitative measurement of insulin in Porcine/Canine serum and plasma (EDTA) For Research Use Only. Not For Use In Diagnostic Procedures. Catalog Number: 80-INSPO-E01
More informationliquicolor (AMP Buffer, IFCC) Design Verification
Design Verification (AMP Buffer, IFCC) liquicolor 1 Introduction... 2 2 Imprecision... 2 3 arity and Detection Limit... 2 3.1 arity... 2 3.2 Detection Limit... 3 4 Comparison of Methods... 3 5 Stability...
More informationSee external label 2 C-8 C = C-REACTIVE PROTEIN (CRP) LATEX SLIDE TEST
CORTEZ DIAGNOSTICS, INC. 21250 Califa Street, Suite 102 and 116, Woodland Hills, CA 91367 Tel: (818) 591-3030 Fax: (818) 591-8383 onestep@rapidtest.com technicalsupport@rapidtest.com www.rapidtest.com
More informationPorcine/Canine Insulin ELISA
Porcine/Canine Insulin ELISA For the quantitative determination of insulin in porcine or canine serum and plasma. Please read carefully due to Critical Changes, e.g., Calculation of Results. For Research
More informationTABLE OF CONTENTS GENERAL INFORMATION... 1
BIOO RESEARCH PRODUCTS Glucose Assay Kit Manual Catalog #: 5611-01 BIOO Scientific Corp. 2011 TABLE OF CONTENTS GENERAL INFORMATION... 1 Product Description... 1 Procedure Overview... 1 Required Materials
More informationEffect of lipemia interferences in routine clinical Biochemical Tests (Intralаboratory Study)
Standard Scientific Research and Essays Vol 3(7): 187-191, July 2015 (ISSN: 2310-7502) http://www.standresjournals.org/journals/ssre Research Article Effect of lipemia interferences in routine clinical
More informationCase Studies, or Verification Vignettes
Case Studies, or Verification Vignettes 1 Vignette #1 Change from One Automated AST to Another Your lab is changing from one FDA-cleared automated AST to another Is a verification study required? 2 Yes
More informationVetScan UA Urine Analyzer Clinical Performance Larry Lem, PhD & Andrew Rosenfeld, DVM, ABVP
VetScan UA Urine Analyzer Clinical Performance Larry Lem, PhD & Andrew Rosenfeld, DVM, ABVP Abstract Background: The VetScan UA urine strip reader is an analyzer designed to provide semi-quantitative and
More informationTotal Bilirubin Assay Kit Manual Catalog #:
Total Bilirubin Assay Kit Manual Catalog #: 3460-10 TABLE OF CONTENTS GENERAL INFORMATION... 2 Product Description... 2 Procedure Overview... 2 Kit Contents, Storage and Shelf Life... 2 Required Materials
More informationSAMPLE. Glucose Monitoring in Settings Without Laboratory Support
POCT13c Glucose Monitoring in Settings Without Laboratory Support This guideline focuses on performance of point-of-care glucose monitoring systems, with an emphasis on safety practices, quality control,
More informationPolymer Technology Systems, Inc. CardioChek PA Comparison Study
Polymer Technology Systems, Inc. CardioChek PA Comparison Study Evaluation Protocol: Accuracy Precision Clinical Correlation PTS Panels Lipid Panel Test Strips For Use in Comparisons to a Reference Laboratory
More informationRat cholesterol ELISA Kit
Rat cholesterol ELISA Kit Catalog No. CSB-E11706r (96T) This immunoassay kit allows for the in vitro quantitative determination of rat Cholesterol concentrations in serum, plasma and other biological fluids.
More information